A Proof of Concept Study to Investigate the Effect of a New Treatment in Patient With Chronic Pain

Not Applicable

Completed

Conditions: Peripheral Neuropathies
Osteoarthritis

Interventions: Behavioral: Heat Pain Stimuli A
Behavioral: Heat Pain Stimuli B
Behavioral: Neutral Video
Behavioral: Positive Video
Drug: Administration of Placebo capsules
Drug: Administration of T4P1001 capsules

Registration Number: NCT02459197

Lead Sponsor: Tools4Patient

Brief Summary: The purpose of this clinical trial conducted in patients suffering from chronic pain is to study the relationship between individual patients' profile and their analgesic response

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 114

Inclusion Criteria

Are men or women of at least 18 years of age
Diagnosed with Peripheral Neuropathic Pain (PNP) or knee or hip pain attributed to Osteoarthritis (OA) since at least 6 months
Affiliated with national welfare
Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Have given written informed consent approved by the relevant Ethics Committee (EC) governing the study sites
Patients will be required to report pain with a score between 4 and 8 inclusive on the mean Average Pain Score (APS) during the baseline period preceding randomization and to have completed at least 10 days of pain assessments in their diary between Visit 1 and Visit 2. If more than 10 days were completed, the mean APS will be calculated on the last 10 ones.

Inclusion Disease Criteria:

Diagnosis criterium for PNP: Patient with chronic PNP supported by a distinct neuroanatomical plausible distribution with sensory signs and symptoms, and consecutive to one of the following causes: a traumatic event, a surgical procedure (excluding limb amputation), radiculopathy, post- herpetic or post- zoster neuralgia, diabetic polyneuropathy or post chemotherapy. Diagnosis will have to be confirmed by the DN4 questionnaire at the screening visit (pain is considered as neuropathic if DN4 score ≥ 4)
Diagnosis criterium for OA: Patient with a unilateral or bilateral OA of the knee or hip diagnosed according to the American College of Rheumatology (ACR) criteria based on clinical and radiographic evidence (Altman et al. 1986). The clinical diagnosis of OA will be confirmed by the ACR clinical and radiographic criteria for classification of idiopathic OA of the knee or hip based upon the following criteria:
1. Knee or hip pain as an average at least half of the time for the last 3 months before screening visit
2. At least 1 of the following 3 conditions: Age > 50 or morning stiffness < 30 minutes or crepitus
3. Kellgren and Lawrence grade > 1 as assessed if possible by an X-ray of the referred joint to confirm the diagnosis. If considered medically required by the Investigator based on patient needs and as part of regular patient management, a new anterior-posterior view X- ray should be obtained and reviewed by Investigator or his delegates to verify that the patient meets the disease diagnostic criteria

Exclusion Criteria

Patient changed his/her " regular analgesic therapy " for PNP or OA in the last 4 weeks prior to Visit 1 or during the study.
Patient's regular analgesic treatment for PNP or OA consists of more than 2 different treatments, with neurostimulation being considered as an analgesic treatment for PNP.
Patient reported unvariable APS and WPS scores between Visit 1 and Visit 2 (systematically the same APS score and the same WPS score reported).
Use or plan to use non-topical corticosteroids during the study.
Have initiated (or plan to initiate) a program (or modify an existing program in frequency and/or intensity) of physiotherapy or behavioral therapy such as pain self-management, hypnosis, sophrology, meditation program within 2 weeks prior to Visit 1 or during the study.
Pregnant, breastfeeding, or willing to be pregnant within 3 months.
Patients with a current or recent history, as determined by the Investigator, of severe, progressive, and/or uncontrolled renal, hepatic, haematological, gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease which would interfere with the patient's participation in the study.
Uncontrolled epilepsy.
Any current primary psychiatric condition, including depression or personality disorders (such as Axe II of Diagnostic and Statistical Manual of Mental Disorders (DSM-IV); personality disorders and mental retardation).
Alcohol dependence or regular use of known drugs of abuse (e.g., amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, and phencyclidine).
Any other relevant medical disorder/acute disease state judged by the Investigator as likely to interfere with the trial or represent a risk for the patient.
Any close relationship with the Investigators or the Sponsor (i.e. belonging to immediate family or subordination link).
Patient under legal protection, according to the national law.
Are persons who have previously received T4P1001, have completed or withdrawn from this study or any other study investigating T4P1001.
Patient currently enrolled in a clinical trial involving use of an investigational drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study, or in an exclusion period according to the national law.

Exclusion Disease Criteria for PNP patients:

Neuropathic pain due to trigeminal neuralgia, central pain or phantom limb pain.
Have initiated, are planning to initiate an electrical stimulation (or neurostimulation) therapy or modify an existing neurostimulation within 4 weeks prior to Visit 1 or during study period.

Exclusion disease criteria for OA patients:

Non-ambulatory due to OA.
Use of lower extremity assistive devices other than a cane such as crutches or walker or a knee brace or a "shoe lift" in relation to OA.
Have used in relation to OA systemic corticosteroids 4 weeks prior to Visit 1; Intra-muscular corticosteroid injections or Intra-articular injection of steroids into the referred knee/hip within 3 months before Visit 1, Intra-articular injection of corticosteroids into any other sites than the referred knee/hip within 4 weeks prior to Visit 1(corticosteroids in topical use are allowed).
Have used viscosupplementation or intra articular injection of hyaluronic acid in the referred joint within 3 months prior to Visit 1.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Neutral Video	-
Placebo	Administration of Placebo capsules	-
T4P1001	Positive Video	-
T4P1001	Heat Pain Stimuli A	-
T4P1001	Administration of T4P1001 capsules	-
Placebo	Heat Pain Stimuli B	-

Primary Outcome Measures

Name	Time	Method
Patient's Change From Baseline of Pain Severity as Measured by the Weekly Means of the Daily Average Pain Scores (APS) During 4 Weeks of Treatment	Time zero equals baseline (Day-28 to Day-14) up to Day 36	11-point Numeric Rating Scale (NRS); the 11 NRS scale ranges from 0 (No pain) to 10 (pain as bad as you can imagine); the baseline APS (weekly mean of the daily average pain score) was computed on the 7 last days before Visit 2 with available APS values; similarly, the end-of-treatment APS (or APS Week 4) was computed on the 7 last days before Visit 4 with available APS values.

Secondary Outcome Measures

Name	Time	Method
Patient's Change From Baseline of Investigator and Patient Global Assessment of Changes (IGAC and PGAC)	Time zero equals baseline (Day-28 to Day-14) up to Day 29	IGAC and PGAC are subjective evaluations using a NRS with 0 meaning "best condition" and 10 "worst condition"
Patient's Change From Baseline of Heat Pain Threshold From Baseline to End of Treatment	Time zero equals baseline (Day 1) up to Day 29	celcius degree, arithmetic average of 6 tests.
For Osteoarthritic Patients Only: Patient's Change From Baseline of Osteoarthritic Physical Function, Pain and Stiffness as Assessed by Western Ontario and MacMaster (WOMAC) Scales From Baseline to End of Treatment	Time zero equals baseline (Day-28 to Day-14) up to Day 29	The WOMAC (Bellamy et al., 1988) is a patient-rated instrument that measures OA symptoms. The questionnaire contains 5 pain questions, 2 stiffness questions, and 17 physical function questions (24 questions total). Each question utilizes a 5-points Numeric Rating Scale (NRS) between 0-4; from 0=none to 4=extreme. Range of possible subscale scores: pain=0-20, stiffness=0-8 and physical function=0-68; higher scores for each subscale indicate worse outcomes. The WOMAC was completed at each Visit except for Visit 5 by OA patients only.
Patient's Change From Baseline of Pain Severity as Measured by the Brief Pain Inventory (BPI)	Time zero equals baseline (Day-28 to Day-14) up to Day 29	BPI is a self-reported scale that measures the severity of pain and the interference of pain on function (Charles S. Cleeland © 2009). In the short form of BPI, there are 4 questions assessing worst pain, least pain, actual pain and average pain in the past 24 hours. The severity scores range from 0 (no pain) to 10 (pain as bad as you can imagine). There are 7 questions assessing the interference of pain in the past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. The interference scores range from 0 (does not interfere) to 10 (completely interferes).

Trial Locations

Locations (6): CIC Clermont-Ferrand, CHU Clermont-Ferrand
🇫🇷
Clermont-Ferrand, France
Eurofins Optimed
🇫🇷
Gières, France
Clinique Breteche
🇫🇷
Nantes, France
Centre d'Evaluation et Traitement de la Douleur, CHU Saint-Etienne
🇫🇷
Saint-Etienne, France
Institut Curie
🇫🇷
Paris, France
ATC sa
🇧🇪
Liège, Belgium